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Background: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by
sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma
(mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.
Patients and methods: Patients received either first-line everolimus followed by second-line sunitinib at progression (n¼ 238)
or first-line sunitinib followed by second-line everolimus (n¼ 233). Secondary end points were combined first- and second-line
progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble
biomarkers on OS were explored.
Results: At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib.
Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1–26.7] with everolimus-sunitinib and 22.2 months
(95% CI 16.0–29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9–1.6]. Median OS was 22.4 months
(95% CI 18.6–33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8–33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1;
95% CI 0.9–1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everoli-
mus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with
the association being largely independent of treatment sequences.
Conclusions: Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in
patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there
were no unexpected safety signals.
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Introduction
Anti-vascular endothelial growth factor (VEGF) agents and
mammalian target of rapamycin (mTOR) inhibitors are standard
treatment options for patients with metastatic renal cell carcin-
oma (mRCC). Current treatment guidelines for patients with
mRCC recommend a first-line VEGF inhibitor, including suniti-
nib, followed by everolimus at progression [1, 2]. RECORD-3
(REnal Cell cancer treatment with Oral RAD001 given Daily;
ClinicalTrials.gov ID, NCT00903175) was a randomized phase
IIb trial that compared outcomes of everolimus and sunitinib as
first-line therapy, and the sequence of everolimus followed by
sunitinib at progression compared with the opposite (standard)
sequence [3]. In the primary analysis, median progression-free
survival (PFS) was 7.9 months [95% confidence interval (CI)
5.6–8.2] with first-line everolimus and 10.7 months (95% CI 8.2–
11.5) with first-line sunitinib [hazard ratio (HR), 1.43; 95% CI
1.15–1.77]. The noninferiority margin was not achieved; there-
fore, the primary end point was not met. The objective of the final
analyses was to evaluate mature data for secondary end points of
combined first-line and second-line PFS (combined PFS), overall
survival (OS), and safety, and to conduct exploratory analyses of
various biomarkers.
Patients and methods
Patients and study design
RECORD-3 study design has been reported [3]. Briefly, patients who
were 18 years of age with measurable mRCC as per Response
Evaluation Criteria In Solid Tumors version 1.0 (RECIST v1.0) were
included in the study. Prior nephrectomy was not required. Key eligibility
criteria included no prior systemic therapy; Karnofsky performance sta-
tus (KPS)70%; adequate hematologic, liver, and kidney function; and
normal left ventricular ejection fraction. Patients were randomly assigned
1 : 1 to receive either first-line everolimus 10 mg/day or sunitinib 50 mg/
day (4 weeks on, 2 weeks off) until first occurrence of progressive disease
(PD) (RECIST v1.0). Patients then crossed over and continued on the al-
ternative drug until second occurrence of PD. The crossover period was
defined as the time after the end of first-line therapy and before the start
of second-line therapy (crossover to occur within 35 days of
progression).
Objectives and assessments
Key secondary objectives of the RECORD-3 study were to compare com-
bined PFS and OS between the two treatment sequences. The objective of
these final analyses was to assess mature data for combined PFS, OS, and
adverse events (AEs). OS by histologic subtypes (clear cell and nonclear
cell) and the impact of neutrophil lymphocyte ratio (NLR) and cytokines
on OS were evaluated as exploratory end points.
Tumor assessments (RECIST v1.0) were carried out every 12 weeks
from randomization until progression or start of another anticancer
treatment. AEs, physical examination, and blood work were assessed at
baseline and continually thereafter.
Statistical methods
Two criteria were used to declare noninferiority of everolimus compared
with sunitinib in terms of first-line PFS [4]. The first criterion was an esti-
mated HR1.1 and the second criterion was an upper estimated one-
sided 90% confidence bound1.27, which required 318 PFS events so
that fulfillment of first criterion implied the second.
The full analysis set (FAS) included all randomly assigned patients
analyzed according to the assigned study treatment and Memorial Sloan
Kettering Cancer Center (MSKCC) prognosis. The safety population
included all patients who received at least one dose of either study drug
and underwent at least one safety assessment in the first-line period. The
second-line safety population included the subset of patients who
received at least one dose of second-line everolimus or sunitinib. The bio-
marker population included all patients with valid biomarker data.
Combined PFS was defined as the time from randomization to progres-
sion after second-line treatment or death from any cause. Patients who
did not cross over to second-line therapy or who did not experience pro-
gression after the start of second-line treatment or who were alive at data
cutoff for the analysis or at the time of receiving an additional anticancer
therapy were censored at last date of tumor evaluation. No formal sample
size and power calculation were made for combined PFS. OS was defined
as time from randomization to death. The preplanned final OS analysis
occurred at the end of the 3-year follow-up period. No formal power cal-
culation was made for the OS analysis and the expected number of deaths
was 300. As for the primary endpoint, an OS noninferiority margin was
pre-defined. The upper estimated, one-sided 90% confidence bound of
the OS HR was to be1.06 to conclude that OS with EVE-SUN is nonin-
ferior to SUN-EVE. This value of 1.06 corresponds to approximately one
and a half month’s difference in median OS between EVE-SUN and
SUN-EVE. The data cutoff date for the final analysis was 16 June 2014.
The neutrophil to lymphocyte ratio (defined as absolute neutrophil
count from segments and bands, divided by the absolute lymphocyte
count) at baseline was dichotomized (/> median across all patients).
Similarly each soluble biomarker was dichotomized into low/high cate-
gories (as</median across all patients). The associations between
baseline biomarker (NLR) categories and OS were assessed via Cox pro-
portional hazards models, Kaplan–Meier curves, and log-rank tests. The
Kaplan–Meier estimates of the OS function within treatment arm and
biomarker (NLR) category were computed according to the Kaplan–
Meier product-limit method. Median OS times and 95% CIs are pre-
sented for each category. HRs and 95% CIs were estimated from a Cox
proportional hazards model for OS, stratified by MSKCC risk groups,
with terms for randomized first-line treatment, baseline biomarker
(NLR), and treatment-by-biomarker (NLR) interaction. Additional in-
formation is presented as supplementary material, available at Annals of
Oncology online.
Results
Patients
From October 2009 to June 2011, 471 patients (FAS population)
were enrolled and randomly assigned to receive either first-line
everolimus followed by second-line sunitinib at progression
(n¼ 238) or first-line sunitinib followed by second-line everoli-
mus (n¼ 233). There were 469 patients in the safety population.
In the primary analysis, baseline characteristics were generally
balanced between treatment arms (Table 1).
Patient disposition and treatment duration at final
OS analysis
At final OS analysis, seven patients (3%) were still receiving first-
line everolimus (treatment duration range, 3.1–4.9 years) and
four patients (2%) were still receiving first-line sunitinib (treat-
ment duration range, 3.1–4.2 years). In the first-line setting, me-
dian duration of exposure was 5.6 months for everolimus and 8.3
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months for sunitinib. Among patients who discontinued first-
line treatment, 128 (55%) crossed over from everolimus to suni-
tinib and 116 (51%) crossed over from sunitinib to everolimus.
The primary protocol-related reason for not crossing over was
ineligibility, which included poor performance status or decline
in condition primarily related to PD, brain metastases, or persist-
ent AE (Figure 1). Seven patients (6%) were still receiving
second-line sunitinib and four patients (3%) were still receiving
second-line everolimus. In the second-line setting, median dur-
ation of exposure was 3.4 months for everolimus and 5.7 months
for sunitinib. The most common reason for treatment discon-
tinuation was disease progression (67%, everolimus; 61%, suniti-
nib). Median duration of follow-up was approximately 3.7 years.
Combined PFS and OS at final OS analysis
At final OS analysis, median combined PFS was 21.7 months
(95% CI 15.1–26.7) with sequential everolimus and sunitinib and
22.2 months (95% CI 16.0–29.8) with sequential sunitinib and
everolimus (HREVE-SUN/SUN-EVE, 1.2; 95% CI 0.9–1.6)
(Figure 2A). Censoring rates were 56% for sequential everolimus
and sunitinib and 57% for sequential sunitinib and everolimus.
The primary reason for censoring was no timely crossover to
second-line therapy, which led to questionable robustness of
Kaplan–Meier estimates and might have confounded the HR
estimate.
Overall, 64% of patients in each treatment arm died. Median
OS was 22.4 months (95% CI 18.6–33.3) for sequential everoli-
mus and sunitinib and 29.5 months (95% CI 22.8–33.1) for se-
quential sunitinib and everolimus (HREVE-SUN/SUN-EVE, 1.1; 95%
CI 0.9–1.4) (Figure 2B). The two-sided 80% CI upper limit of
1.27 was above the noninferiority margin of 1.06. Median OS was
similar between treatment arms among patients with clear cell
mRCC and those with nonclear cell mRCC. In the clear cell
group, median OS was 23.9 months for sequential everolimus
and sunitinib (n¼ 207) and 30.2 months for sequential sunitinib
and everolimus (n¼ 197) (HREVE-SUN/SUN-EVE, 1.1; 95% CI 0.9–
1.4). Among patients with nonclear cell mRCC, median OS was
16.2 months for sequential everolimus and sunitinib (n¼ 29)
and 16.8 months for sequential sunitinib and everolimus
(n¼ 35) (HREVE-SUN/SUN-EVE, 1.0; 95% CI 0.6–1.8).
In each first-line treatment arm, 18% (n¼ 43) of patients did
not cross over to per-protocol second-line treatment, but did
subsequently receive off-protocol antineoplastic therapy after
study drug discontinuation. Among those patients, 14 in the
first-line everolimus arm received second-line sunitinib and 6 in
the first-line sunitinib arm received second-line everolimus. After
second-line treatment discontinuation, 50% of the patients
from each treatment arm received subsequent antineoplastic
therapy.
AE profile
The most frequently reported AEs during first-line everolimus
and first-line sunitinib, respectively, were stomatitis (53% and
58%), fatigue (47% and 53%), and diarrhea (40% and 58%). The
rates of grade 3 and 4 AEs suspected to be related to first-line ther-
apy were 47% with everolimus and 63% with sunitinib. At final
OS analysis, the most frequently reported AEs during second-line
everolimus were fatigue (35%), stomatitis (32%), and anemia
(32%) (Table 2). The most frequently reported AEs during
second-line sunitinib were diarrhea (54%), fatigue (38%), nausea
(38%), decreased appetite (33%), and hypertension (33%)
(Table 2). The rates of grade 3 and 4 AEs suspected to be related
to second-line therapy were 47% with everolimus and 57% with
sunitinib. Within each treatment sequence, the rates of grade 3
and 4 AEs suspected to be related to treatment were 62% in the
sequential everolimus and sunitinib arm and 71% in the sequen-
tial sunitinib and everolimus arm.
In the safety population there were 34 (14%) on-treatment
deaths in the first-line everolimus arm (n¼ 238) and 15 (6%) on-
treatment deaths in the first-line sunitinib arm (n¼ 231). In the
second-line safety population there were 11 (9%) on-treatment
deaths of patients who received everolimus (n¼ 116) and 12
(9%) on-treatment deaths of patients who received sunitinib
(n¼ 128).
Prognostic factors
Our previous research work, based on a survey of a large panel of
soluble molecules involved in multiple biological processes,
showed that the baseline levels of 12 biomarkers were prognostic
indicators for the first-line PFS [5]. With the availability of OS
data, the prognostic values of these biomarkers were evaluated.
All 12 biomarkers were also associated with OS in the same direc-
tion as they were associated with first-line PFS, always with an as-
sociation of a higher biomarker level and a shorter OS
(supplementary Table S1, available at Annals of Oncology online).
The impact of these biomarkers on OS by the treatment sequence
Table 1. RECORD-3 primary analysis summary of key characteristics and
primary end point [4]
Key baseline
characteristics
First-line
everolimus arm
(n¼ 238)
First-line
sunitinib arm
(n¼ 233)
Age, years, median (range) 62 (20–89) 62 (29–84)
Sex, men/women, n (%) 166 (70)/72 (30) 176 (76)/57 (25)
KPS, n (%)
90 158 (66) 181 (78)
80 61 (26) 43 (19)
70 18 (8) 8 (3)
Missing 1 (<1) 1 (<1)
Predominant tumor histology subtype, n (%)
Clear cell 205 (86) 197 (85)
Nonclear cell 31 (13) 35 (15)
Missing 2 (<1) 1 (<1)
Prior nephrectomy, n (%) 159 (67) 156 (67)
MSKCC risk group, n (%)
Favorable 70 (29) 69 (30)
Intermediate 132 (56) 131 (56)
Poor 35 (15) 32 (14)
Primary end point
Median PFS, months (95% CI) 7.9 (5.6–8.2) 10.7 (8.2–11.5)
HR, 1.43 (95% CI 1.15–1.77)
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was often similar. Whenever there was a difference, however, the
impact was often more evident on the everolimus-sunitinib se-
quence than the standard sequence. Of note, the baseline levels of
these cytokines were well balanced between the treatment se-
quences, supporting the adequacy of the OS comparison analysis.
Elevated NLR has recently been shown as a poor prognostic
factor for survival in multiple cancer types, including RCC [6, 7].
A similar prognostic signal was confirmed in the RECORD-3
population, although the magnitude was slightly lower than that
reported in a meta-analysis (HR 1.85 versus 2.27) (supplemen-
tary Table S2, available at Annals of Oncology online). The associ-
ation between NLR and the OS was largely independent of the
treatment sequences (supplementary Figure S1, available at
Annals of Oncology online).
Discussion
On the basis of the first-line PFS HR estimates (primary efficacy
analysis), EVE did not demonstrate noninferiority compared
with SUN. The inferiority of EVE versus SUN could also not be
formally concluded. However, the different safety profile as well
as the observed shorter median PFS for first-line EVE [with an
HR of 1.4 (95% CI 1.2–1.8)] were deemed to be clinically relevant
supporting the standard sequence of first-line sunitinib fol-
lowed by everolimus at progression for patients with mRCC [3].
Results of the RECORD-4 trial provided additional insight
into outcomes of patients with mRCC treated with second-line
everolimus (Clinicaltrials.gov identifier, NCT01491672) [8].
In RECORD-4, PFS, and OS were evaluated for second-line ever-
olimus in three cohorts of patients that were enrolled into the
trial based on their first-line therapy. Results of RECORD-4
showed a median PFS of 7.8 months in the overall population
and in the cohort of patients who received first-line treatment
with other anti-VEGF agents (sorafenib, bevacizumab, pazopa-
nib, tivozanib, or axitinib) and a median PFS of 5.7 months for
the cohort of patients who received first-line sunitinib. At final
OS analysis, median OS was 23.8 months in the overall popula-
tion and in the first-line sunitinib cohort, and 17.2 months in the
other previous anti-VEGF therapy cohort. These results con-
firmed the survival benefit of second-line everolimus after receiv-
ing first-line sunitinib or various other first-line anti-VEGF
therapies. However, three new agents that were evaluated in stud-
ies of patients previously treated with one or two VEGF-targeted
agents have shown survival advantages over everolimus. Results
of one study, the phase III CheckMate-025 trial, showed a longer
median OS with nivolumab (an inhibitor of the programmed
death-1 pathway) over everolimus (25.0 and 19.6 months, re-
spectively) in VEGF-refractory patients with mRCC; median PFS
was similar for both agents (4.6 and 4.4 months, respectively;
P¼ 0.11) [9]. In another study, results of the phase III METEOR
trial showed a PFS and OS advantage of cabozantinib (an inhibi-
tor of VEGFR2 and c-MET) over everolimus (median PFS 7.4
and 3.9 months, respectively; P<0.0001: median OS 21.4 and
16.5 months, respectively; P¼ 0.00026) [10]. Phase II study results
showed PFS and OS benefits with lenvatinib (a multikinase inhibitor)
combined with everolimus compared with everolimus monotherapy
(median PFS 14.6 versus 5.5 months, respectively; P¼ 0.0005:
Randomly assigned
(N = 471)
Everolimus → sunitinib
(n = 238)
Ongoing 7 (3)
Discontinued 231 (97)
Crossed over to second-line
Primary reasons
Death
Withdrew consent
Ineligible‡
128 (55)
103 (45)
40 (37)
37 (34)
17 (16)
Protocol deviation 8 (7)
Not applicable§ 6 (6)
4 (2)
227 (97)
116 (51)
111 (49)
43 (38)
23 (20)
27 (24)
10 (9)
11 (10)
Safety population
(n = 238)
First-line, n (%)
Did not cross over to second-line,† n (%)
Ongoing
Discontinued
Crossed over to second-line
Primary reasons
Death
Withdrew consent
Ineligible‡
Protocol deviation
Not applicable§
First-line, n (%)
Did not cross over to second-line,† (%)
FAS population
(n = 238)
FAS population
(n = 233)*
Safety population
(n = 231)
Never received treatment
(n = 2)
Sunitinib → everolilmus
(n = 233)
Figure 1. CONSORT diagram. *Indicates two patients randomly assigned to receive sunitinib did not receive treatment. †Indicates after ﬁrst-
line treatment discontinuation. ‡Indicates ineligibility included poor performance status or decline in condition primarily related to progres-
sive disease, brain metastases, or persistent adverse events. §Patients crossed over after the cutoff date. FAS, full analysis set.
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median OS, 25.5 and 15.4 months, respectively; P¼ 0.024) [11].
Recent regulatory approval of these new agents has changed the
second-line treatment landscape for patients with mRCC.
Survival of patients with mRCC has improved since the advent
of targeted therapy. For example, results of pivotal phase III stud-
ies of first-line VEGF-targeted agents (sunitinib, sorafenib, pazo-
panib, and bevacizumab) showed that median OS ranged from
19.3 months with sorafenib to 26.4 months with sunitinib [12,
13]. As the treatment landscape changed and targeted agents were
developed for second- and later-line use in patients with mRCC,
patient survival continued to improve. Results of pivotal studies
of targeted agents in the second- or later-line showed a median
OS of 14.8 months for patients who received everolimus follow-
ing treatment with sunitinib or sorafenib (or both) and a median
OS of 15.2 months for patients who received axitinib following
treatment with sunitinib [14, 15]. The RECORD-3 final OS ana-
lysis can only be considered descriptive given that the study failed
to meet its primary endpoint. In this final OS analysis, the median
OS of 29.5 months for sequential sunitinib and everolimus sug-
gests an improvement from earlier trials in which access to a
second-line mTOR inhibitor was not readily available, and the
median OS is comparable with that of more recent trials in which
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Figure 2. (A) Kaplan–Meier estimates of combined ﬁrst-line and second-line PFS in the FAS population. (B) Kaplan–Meier estimates of OS in
the overall population.
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patients receiving a first-line VEGFR targeted therapy had access
to a second-line agent [16]. The observed shorter median OS for
the EVE-SUN sequence (22.4 months) versus SUN-EVE (29.5
months), which is associated with an HR (EVE-SUN versus
SUN-EVE) of 1.1 (95% CI 0.9–1.4), is considered consistent with
the primary endpoint PFS results. Although not supported by
any formal statistical testing, this observed improved median OS
in SUN-EVE was also deemed clinically relevant to further sup-
port the standard treatment sequence of sunitinib followed by
everolimus.
In RECORD-3, the rate (50%–54%) of crossover to second-
line therapy was surprisingly low; however, the median combined
PFS of 22.2 months for sequential sunitinib and everolimus is a
novel end point that was not previously established in prospective
trials, and it can serve as a new reference in clinical trials designed
to study sequential therapy. Because of high censoring rates, there
are limitations to the interpretation of our combined PFS results.
In this RECORD-3 final OS analysis, AEs remained consistent
with the known safety profiles of everolimus and sunitinib. The
most commonly reported AEs with second-line everolimus were
fatigue, stomatitis, and anemia and with second-line sunitinib
were diarrhea, fatigue, and nausea. No new safety signals were
identified for either agent.
The predictive values of biomarkers could not be robustly as-
sessed because they were confounded by the cross-over design.
Evaluation of the soluble biomarkers, which were identified as
prognostic factors for first-line PFS, showed that they are also
likely prognostic for OS, often independent of the treatment se-
quences. These prognostic factors and the NLR may be con-
sidered as stratification factors in future trial designs or as
impactful covariates in the statistical analyses, especially in
randomized trials of relatively small sample sizes, to avoid drastic
imbalances.
Conclusions
Final OS analysis results are consistent with initial results and fur-
ther support the sequence of VEGFR-targeted therapy followed
by everolimus, in clear cell and nonclear cell mRCC, at progres-
sion. The AE profiles of everolimus and sunitinib were consistent
with those previously reported, and there were no unexpected
safety signals.
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